Nephros Stock Forecast, Price & News

Today's Range N/A
50-Day Range
52-Week Range N/A
Volume1,370 shs
Average Volume13,726 shs
Market Capitalization$91.65 million
P/E RatioN/A
Dividend YieldN/A

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

Nephros logo

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.96 out of 5 stars

Medical Sector

326th out of 2,210 stocks

Surgical & Medical Instruments Industry

36th out of 185 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nephros (NASDAQ:NEPH) Frequently Asked Questions

Is Nephros a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros
or view top-rated stocks.

What stocks does MarketBeat like better than Nephros?

Wall Street analysts have given Nephros a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nephros wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nephros?

Nephros saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 17,300 shares, a decline of 44.7% from the June 30th total of 31,300 shares. Based on an average trading volume of 10,200 shares, the short-interest ratio is currently 1.7 days. Approximately 0.2% of the company's stock are short sold.
View Nephros' Short Interest

When is Nephros' next earnings date?

Nephros is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Nephros

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) announced its quarterly earnings data on Thursday, May, 6th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. The business earned $2.74 million during the quarter, compared to analysts' expectations of $2.70 million. Nephros had a negative net margin of 47.27% and a negative trailing twelve-month return on equity of 30.24%.
View Nephros' earnings history

What guidance has Nephros issued on next quarter's earnings?

Nephros issued an update on its second quarter 2021 earnings guidance on Thursday, July, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.20 million-$2.20 million, compared to the consensus revenue estimate of $2.80 million.

What price target have analysts set for NEPH?

3 equities research analysts have issued twelve-month target prices for Nephros' shares. Their forecasts range from $12.50 to $16.00. On average, they expect Nephros' stock price to reach $13.83 in the next year.
View analysts' price targets for Nephros
or view top-rated stocks among Wall Street analysts.

Who are Nephros' key executives?

Nephros' management team includes the following people:
  • Mr. Andrew Astor, CEO, CFO, Pres & Director (Age 64, Pay $309.01k)
  • Mr. Daron G. Evans, Chief Exec. Officer of Specialty Renal Products, Inc (Age 47, Pay $300.18k)
  • Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
  • Mr. Shane Sullivan, VP of Sales
  • Mr. Wesley S. Lobo, Chief Marketing Officer (Age 44)
  • Mr. Greg Lucas, Pres of Aether Water Systems

Who are some of Nephros' key competitors?

What is Nephros' stock symbol?

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Nephros make?

Nephros has a market capitalization of $0.00 and generates $8.56 million in revenue each year. The company earns $-4,770,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Nephros have?

Nephros employs 27 workers across the globe.

What is Nephros' official website?

The official website for Nephros is

Where are Nephros' headquarters?

Nephros is headquartered at 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.